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Taste assessment in an increasingly important aspect of formulation development, particularly for paediatric
medications. Electronic taste sensing systems have the potential to oﬀer a rapid, objective and safe method
of taste assessment prior to the use of more costly human panels or animal models. In this study, the ability
of the TS-5000Z taste sensing system to assess the taste masking eﬃciency of (2-hydroxypropyl)-b-
cyclodextrin (HP-b-CyD) complexes with ranitidine hydrochloride was evaluated in order to explore the
potential of the biosensor approach as a means of assessing taste masking by inclusion complexation.
Nuclear magnetic resonance (NMR) spectroscopy and molecular docking studies were employed to
identify and examine the interaction between ranitidine hydrochloride and HP-b-CyD. Taste-masking
eﬃciencies were determined by the Euclidean distance between taste-masked formulations and the
pure drug substance on a PCA score plot. The results showed that with increasing molarity of HP-b-CyD
in the formulation, the distance from ranitidine hydrochloride increased, thus indicating a signiﬁcant
diﬀerence between the taste of the formulation and that of the pure drug. NMR studies also provided
strong supporting evidence for the complexation between HP-b-CyD and ranitidine hydrochloride, with
the H30 region of the former identiﬁed as the most likely binding site for the drug. Molecular docking
studies suggested that the dimethylamino and diamine groups of the drug form direct hydrogen bonds
with the hydroxyl oxygen atoms of HP-b-CyD, while the furan ring docks in close proximity to H30. This
study has demonstrated that the biosensor system may provide quantitative data to assess bitterness of
inclusion complexes with HP-b-CyD, while spectroscopic and modelling studies may provide
a mechanistic explanation for the taste masking process. This in turn suggests that there is a role for
biosensor approaches in providing early screening for taste masking using inclusion complexation and
that the combination with mechanistic studies may provide insights into the molecular basis of taste and
taste masking.Introduction
Taste is oen a key factor in the development of pharmaceutical
formulations, particularly for paediatric and elderly patients,
due to the associated direct inuence on patient adherence.1
The ve specic tastes include saltiness, sourness, bitterness,
sweetness and umami; bitterness is the most problematic for
pharmaceutical formulations due to its intuitive associationmacy, 29-39 Brunswick Square, London
ac.uk
emistry, 20 Gordon Street, LondonWC1H
tion (ESI) available. See DOI:with toxicity. The sensory mechanism of signal transduction
following binding of a molecule to a taste receptor varies
depending on the taste in question. For example, saltiness is
mediated by sodium ion ux through apical sodium channels,
sourness is mediated through a hydrogen ion blockade of
potassium or sodium channels while sweetness and bitterness
are transmitted via G protein-coupled receptors,2 with the
perception of bitterness beingmediated by bitter taste receptors
(T2Rs) in the oral cavity.3
Ranitidine hydrochloride (Fig. 1) is an H2-receptor antago-
nist that reduces acid production in the stomach and is
commonly used to treat gastrointestinal diseases such as
duodenal ulcer, reux oesophagitis and Zollinger–Ellison
Syndrome. It is included on the World Health Organisation's
List of Essential Medicines which species medicines requiredThis journal is © The Royal Society of Chemistry 2018
Fig. 1 Chemical structure of (a) (2-hydroxypropyl)-b-cyclodextrin





















































































View Article Onlinefor basic healthcare.4 However, ranitidine hydrochloride is also
known to have a bitter taste and a sulphur-like odour.5 These
may potentially be signicant barriers to patient adherence,
hence the exploration of taste-masking approaches is of rele-
vance for this drug.
There are various taste-masking techniques which may be
used to inhibit bitter taste.6 For solid oral dosage forms, poly-
mer coating of capsules and tablets or monolithic systems such
as polymer or lipid extrudates may be used;7 these approaches
may be of less use for paediatric patients for whom swallowing
solid dosage forms can be challenging. Liquid formulation
approaches may include chemical modications to the drug,
microencapsulation, or simply the addition of taste masking
excipients such as sugars, sweeteners and sweetness
enhancers.8 Complexation by cyclodextrins or ion exchange
resins can also be considered. Cyclodextrins (CDs) belong to
a class of cyclic oligosaccharides composed of a-D-glycopyr-
anose units linked by a-1,4 glycosidic bonds. The a-, b- and g-
cyclodextrins are widely used examples of, with six, seven and
eight D-glycopyranose units, respectively. Cyclodextrins exhibit
a central cavity lined with carbon and oxygen atoms of the
glucose residues and a hydrophilic exterior made up of alco-
holic hydroxyl groups. As a result, cyclodextrins possess the
ability to include guest molecule inside their cavities, forming
inclusion complexes. These inclusion complexes can enhance
drug solubility, mask bitter taste of the active pharmaceutical
ingredient (API) and prevent degradation of drugmolecules.9 (2-
Hydroxypropyl)-b-cyclodextrin (HP-b-CyD), a hydroxyalkyl
derivative of b-CD (Fig. 1), was introduced to improve aqueous
solubility of b-CD as well as to enhance inclusion capability.10
This chemically modied derivative of b-CD has also displayed
an enhanced safety prole compared to its parent compound.11
The three main approaches to taste-masking assessment are
human taste panels, animal models and in vitro analytical
techniques. Taste assessment by a human panel is challenging
with regards to cost, time and unknown toxicity status of new
drug entities. Moreover, the approach is susceptible to varia-
tions in the physiology of both the various patient populations
and the individuals concerned. Animal models such as the
rodent BATA model have also shown great promise in assessingThis journal is © The Royal Society of Chemistry 2018the taste of APIs with comparable results to human taste panel
data, however further validation work is still needed.12,13 In vitro
analytical techniques include the use of dissolution testing and
electronic taste sensing systems. Dissolution testing detects the
amount of free drug in a solution as a function of time but is
a crude indication of the experience of taste.14 Electronic taste
sensing systems are composed of multichannel taste sensors,
involving a series of lipid/polymer membrane coatings.15 These
multichannel sensors measure a pattern of signals associated
with the membrane potentials which may then be associated
with taste quality.16,17 These systems therefore have the poten-
tial to oﬀer an objective and safe method for taste-masking
assessment, although validation remains a matter of ongoing
investigation.18 The two most commonly used, commercially
available taste-sensing systems are Alpha Astree II (Alpha MOS,
Toulouse, France) and TS-5000Z (Insent Inc., Atsugi-shi, Japan);
in this study, the latter was used. The taste sensing system is
made up of a working electrode with a lipid/polymer membrane
used to detect taste substances, a handle and a data processing
unit.
The system is designed to detect taste in a similar manner to
human gustatory sensation where lipid/polymer membranes,
transducer and statistical analysis in the systemmirror the taste
buds, neural transmission and cognition in the thalamus in
humans respectively. Taste substances cause changes in electric
charge density of the lipid/membrane surface and/or ion
distribution near the surface of the membrane.19 The total
electric change is then given as the response membrane electric
potential for the substances. While most studies exploring the
use of taste sensors for pharmaceuticals have focused on
assessing the quantitative response for particular drug systems,
there is an emerging emphasis on looking at how the approach
may be used to assess taste masking strategies. In particular,
a previous investigation has compared the ability of the e
tongue approach with an animal model to assess cyclodextrin as
a means of taste masking praziquantel.20
The rationale for using an electronic taste sensing system to
determine taste-masking eﬀects is that it enables one to
measure the activity of molecules within a formulation based on
its non-specic multi-sensor approach. In addition, the sensors
are able to interact with diﬀerent chemical structures, which
allows one to assume an overall impression rather than to
determine the concentration of the drug substance. If a (log-
linear) dependency between concentrations of the bitter
tasting drug substance and the sensor response exists, good
results for the determination of taste-masking properties can be
expected. Since the underlying measurement principle is
potentiometric, sensor responses will most likely be derived
from charged molecules. Therefore, it is reasonable to deduce
that any reduction in sensor response is based on a lower
exposure to the drug substance due to the taste-masking
approach in question.21
In this study we have explored the potential of the approach
to recognize the role of inclusion complexation as a means of
masking taste in relation to the complexation process itself. In
particular, we evaluate the eﬀectiveness of HP-b-CyD to reduce





















































































View Article Onlinerelation to the complex formation process, as assessed using
nuclear magnetic resonance spectroscopy (NMR); we also
investigate molecular docking studies of ranitidine complexa-
tion with HP-b-CyD in order to obtain some basic information
on the likely conguration of any such complex. In this manner
we intend to correlate (or otherwise) the measured assessment
of taste with the structure of the associated complex, thereby
facilitating the use of the biosensor approach to provide an




quinine hydrochloride dihydrate, potassium chloride, tartaric
acid, potassium hydroxide, hydrochloric acid (32%) were
purchased from Sigma-Aldrich Chemie GmbH (Steinheim,
Germany). Absolute ethanol was purchased from Fisher
Chemical (Geel, Belgium). The inner solution (3.33 mol l1
potassium chloride in saturated silver chloride) for sensors and
reference electrodes of the taste sensing system was provided by
Insent Inc. (Atsugi-shi, Japan).Electronic tongue measurements
The Insent TS-5000Z electronic tongue (Insent Inc., Atsugi-shi,
Japan) was equipped with four lipid membrane sensors and
two corresponding reference electrodes; three represent bitter-
ness (SB2AC0, SB2AN0 and SB2C00) and one represents
astringency (SB2AE1). SB2AC0 is dedicated to bitter cationic
substances, SB2AN0 is dedicated to bitter cationic and neutral
substances while SB2C00 is dedicated to bitter anionic
substances. Each of these sensors was lled with 0.2 ml of inner
solution, while the reference electrodes were lled with 0.4 ml
of inner solution. All sensors were immersed in standard solu-
tion (see below) for 24 hours as preconditioning before
measurement.
Two washing solutions for negatively and positively charged
sensors were prepared respectively. For the negatively charged
sensors, 30% ethanol in distilled water with 100 mM of hydro-
chloric acid was used, while for the positively charged sensors,
100 mM of potassium chloride with 10 mM potassium
hydroxide were added to 30% ethanol. The standard solution
serving as cleaning and reference solution was prepared by
dissolving 0.3 mM tartaric acid and 30 mM potassium chloride
in distilled water.
Sensor checks were carried out before every measurement to
ensure the sensors were working in the correct mV range; each
sample was measured four times. The rst run was discarded as
recommended by the supplier to allow for sensor conditioning.
The assessment cycle consisted of measuring the reference
solution (Vr), the sample solution (Vs), a short cleaning proce-
dure (2  3 s), measurement of the aer taste (Vr0) and nally
followed by a cleaning procedure for 330 s. The sensor output
for taste, also called relative value (R) was determined with3566 | RSC Adv., 2018, 8, 3564–3573respect to the initial measured sensor response to the reference
solution (Vr).
R ¼ Vs  Vr (1)
Test solutions
Six diﬀerent concentrations of ranitidine hydrochloride solu-
tions, (between 0.06 mg ml1 and 1.50 mg ml1) were prepared
in distilled water. Quinine hydrochloride dihydrate (molecular
mass ¼ 396.91 g mol1) and HP-b-CyD (molecular mass ¼
1380 gmol1) solutions were prepared in the samemolarity as
the ranitidine hydrochloride (molecular mass¼ 350.86 gmol1)
solutions so to allow for better comparability (Table S1†).
Five taste-masked formulations with diﬀerent molar ratios of
ranitidine hydrochloride to HP-b-CyD (1 : 1, 1 : 2, 1 : 3, 1 : 4 and
1 : 5) were prepared by mixing ranitidine hydrochloride powder
with increasing amount of HP-b-CyD. The concentrations of HP-
b-CyD in each of these taste-masked formulations are given in
Table S2.†Data analysis
In the assessment of taste-masking properties, the sensor
signals of the taste-masked formulations are compared with
that of the pure drug solution using principal component
analysis (PCA). PCA aims to summarize and reduce multidi-
mensional data by transforming sensor signals to principal
components, in order to describe the measured formulation
samples in a new space with fewer dimensions. The PCA map is
presented in a two-dimensional graph with the discriminating
factors as principal component 1 (PC1) on the x-axes and
principal component 2 (PC2) on the y-axes. As a result, the PCA
map can be evaluated visually by the location of the measured
samples. Since the pure drug solution exhibits a known
unpleasant bitter taste, the larger the distance between the pure
drug and the formulations, the greater the diﬀerence in taste.
This distance between measured samples, known as Euclidean
distances, can be calculated by equation shown in (2), where p
and q represent the samples and n is the number of variables
used for the model.22 Data processing, graphical representation
and statistical interpretation of results were performed using








Solutions of samples were prepared in 99.96% D2O (Cambridge
Isotope Laboratories). In the rst instance, 1H-NMR spectra of
HP-b-CyD and ranitidine hydrochloride were recorded sepa-
rately. In order to examine the complexation process between
ranitidine hydrochloride and HP-b-CyD in solution, two stock
solutions of 40 mM were prepared. Based on these two equi-
molar solutions, three samples containing both ranitidine
hydrochloride and HP-b-CyD were prepared. This was achievedThis journal is © The Royal Society of Chemistry 2018
Fig. 2 Sensor response curve for ranitidine hydrochloride showing






















































































View Article Onlineby mixing the two solutions at varying proportions, so that
a range (0 < r < 1) of the ratio r¼ [X]/([H] + [G]) was sampled.23 In
this experiment X ¼ [H] and [H] and [G] are the total concen-
trations of the host (HP-b-CyD) and guest (ranitidine hydro-
chloride), respectively. Therefore, the total concentration [H] +
[G] ¼ [M] ¼ 40 mM was kept constant for each solution. Table
S3† illustrates the preparation process.
Solution 1H and 13C NMR spectra were recorded on a Bruker
Avance III 600 MHz NMR spectrometer equipped with a 5 mm
cryoprobe (1H 600.13 MHz and 13C 150.90 MHz). Data acquisi-
tion and processing were performed using standard TopSpin
(version 3.2) soware. 1H and 13C chemical shis were cali-
brated using dioxane shis in D2O (
1H 3.75 ppm, 13C 67.19
ppm). NMRmeasurements were carried out at 298 K. A set of 2D
experiments were used for assignment of 1H and 13C signals,
including COSY for 1H–1H correlations via proton JHH
couplings, NOESY for 1H–1H correlations via NOEs (nuclear
Overhauser eﬀects) and HSQC for 1H–13C correlations via one-
bond 1JCH couplings. Standard Bruker pulse sequences sel-
digpzs and selcssfdizs were used for acquisition of selective 1D
TOCSY spectra.Molecular modelling
The structure of HP-b-CyD was downloaded from the Protein
Data Bank (code 2y4s) and treated as the receptor molecule. The
structure of ranitidine was sketched in LigEdit module, charges
assigned and docked using the ICM-Pro Molecular Modelling
Suite (http://www.molso.com). Grid maps of size 15  15  10
A3 were generated that encompassed the entire central cavity of
b-cyclodextrin structure. Docking was run with an eﬀort of 5,
storing all alternative conformations of the ligand. A maximum
of 25 docked conformations were generated. The nal confor-
mation was chosen based on strongest interaction energy
between HP-b-CyD and ranitidine. Visualization of the docked
poses was done using Pymol (http://www.pymol.org) and ICM-
Pro Molso molecular modelling package.Fig. 3 Sensor response curve for 2-(hydroxypropyl)-b-cyclodextrin
showing normalised sensor response as a function of concentration (n
¼ 3, mean  S.D.).Results and discussion
Assessment of ranitidine hydrochloride and HP-b-CyD alone
The taste sensing system was rst used to quantify the sensor
response for ranitidine hydrochloride as a function of concen-
tration (Fig. 2). All four sensors presented clear dependency
between concentrations of the drug substance and sensor
responses; it was also observed that the three bitterness sensors
(SB2AC0, SB2AN0 and SB2C00) displayed a positive correlation
whereas the astringency sensor SB2AE1 exhibited a negative
correlation between the two variables. However, it is noticeable
at 0.06 mg ml1 (0.171 mM), sensor output from SB2AC0 spiked
to its maximum before decreasing and following a concentra-
tion-dependent response. Similar observation could be
observed for SB2C00 where sensor output dropped initially at
0.06 mg ml1 (0.171 mM) before rising again and assuming
a logarithmic relationship. Previous authors24 have suggested
that the relationship between concentration and sensorThis journal is © The Royal Society of Chemistry 2018response may be complex and dependent on both the sensor
and the substrate on a case by case basis.
When HP-b-CyD was assessed, both the absolute sensor
responses and the concentration dependencies were weaker as
compared to those of ranitidine hydrochloride (Fig. 3). Anom-
alies in sensor outputs were observed at 0.492 mg ml1 (0.356
mM); SB2AC0 showed a sharp increase at these data points
whereas the other three sensors displayed a fall in sensor
responses. These responses also failed to depict clear depen-
dency with concentrations of the complexing agent. For
example, the sensor outputs from 0.983 mg ml1 (0.713 mM) to
5.90 mg ml1 (4.275 mM) of HP-b-CyD remained relatively
constant without showing signicant increase or decrease. A
plausible explanation could be that the sweet tasting HP-b-CyD





















































































View Article Onlinebitterness sensors.25 It may also be an indication that the TS-
5000Z taste sensing system is less eﬀective in detecting non-
ionic substances such as HP-b-CyD which has a neutral
charge.26 As the measurement principal is potentiometric, the
detection of ranitidine hydrochloride is comparatively
enhanced due to increased conductivity associated with the
cationic molecule.27
Assessment of quinine hydrochloride dihydrate alone
Quinine hydrochloride dihydrate was chosen as the reference
bitter model compound28 so that the taste of ranitidine hydro-
chloride could be expressed in relation to it on a PCA score plot.
According to the European Pharmacopoeia, quinine hydro-
chloride has a bitterness value of 200 000 while ranitidine
hydrochloride has a value of 100 000.29 A value of 200 000
means that 1 g of the substance diluted in 2001 parts of water
still has a bitter taste. This implies that quinine hydrochloride
dihydrate has a stronger bitter taste than ranitidine
hydrochloride.
By comparing the data obtained from both substances, it was
evident that quinine hydrochloride dihydrate elicited greater
sensor responses compared to ranitidine hydrochloride (Fig. 4).
For example, based on sensor SB2AC0, the sensor responses
achieved at 1.50 mg ml1 (4.275 mM) of ranitidine hydrochlo-
ride was 67 mV while the sensor response was 246 mV at
1.697 mg ml1 (4.275 mM) of quinine hydrochloride dihydrate.
The same was shown in sensor SB2AN0 where the sensor
responses at 4.275 mM of ranitidine hydrochloride and quinine
hydrochloride dihydrate were 56 mV and 193 mV correspond-
ingly. The other dissimilarity between these two substances in
terms of sensor response was observed in sensor SB2C00.
Previously for ranitidine hydrochloride, sensor SB2C00 dis-
played a positive correlation between concentration and sensor
response (Fig. 2); however, a negative correlation was presented
with quinine hydrochloride dihydrate. Astringency sensor
SB2AE1, on the other hand, showed similar responses for bothFig. 4 Sensor response curve for quinine hydrochloride dihydrate
showing normalised sensor response as a function of concentration (n
¼ 3, mean  S.D.).
3568 | RSC Adv., 2018, 8, 3564–3573drug substances. This comparison therefore allows us to both
ascertain that, while nevertheless bitter tasting, ranitidine HCl
is less so than quinine hydrochloride and also shows agreement
with the literature assessment of their relative bitterness values.Principal component analysis of pure materials
Principal component analysis (PCA) was used to reduce the
multidimensional space (i.e. responses from four independent
sensors) without losing information. The drug sensor
responses, together with that of HP-b-CyD, are presented on
a PCA score plot (Fig. 5). The concentrations of ranitidine
hydrochloride, quinine hydrochloride dihydrate and HP-b-CyD
represented in this plot are of equal molarities (4.275 mM),
corresponding to 1.50 mg ml1, 1.697 mg ml1 and 5.90 mg
ml1 respectively. In PCA, the dataset is projected onto the
space spanned by the vectors (principal components) that
correspond to the maximum variance of the dataset. Using PCA
the most important information contained in the raw data
could be transformed into the rst principal component (PC-1)
and the second most important is transformed into the second
principal component (PC-2). Plotting of PC-1 versus PC-2 gives
a map which allows the assessment of similarities and diﬀer-
ences between diﬀerent samples. Diﬀerences between samples
were assessed by determining the Euclidean distance between
them aer multivariate data analysis. The greater the Euclidean
diﬀerence between samples, the greater the diﬀerence in taste
response.21
On the PCA map, bitter tasting quinine hydrochloride dihy-
drate and ranitidine hydrochloride were positioned on the right
hand side and bottom le hand side respectively. HP-b-CyD,
representing a benign tasting formulation, was located at the
top le corner of the map. The Euclidean distance (i.e. the
distance between two points on the map) between ranitidine
hydrochloride and HP-b-CyD was calculated to be 2.29 while the
distance between quinine hydrochloride dihydrate and HP-b-
CyD was 3.87, indicating a stronger bitter taste for the latterFig. 5 Principal component analysis (PCA) comparing sensor outputs
of ranitidine hydrochloride with those of quinine hydrochloride dihy-
drate and HP-b-CyD using the following sensors: SB2AC0, SB2AN0,
SB2C00 and SB2AE1.





















































































View Article Onlinedrug which is consistent with the literature. The plot also
demonstrates the ability of the taste sensing system to diﬀer-
entiate the two diﬀerent bitter tasting drug substances as
distinguished by their respective positions on the score plot.
The experiments and associated plots were repeated in their
entirety and both the plots and Euclidean distances were found
to be similar.Fig. 6 Principal component analysis (PCA) representing the inﬂuence
of taste-masked formulations with diﬀerent molar ratios (1 : 1, 1 : 2,
1 : 3, 1 : 4 and 1 : 5) of drug : HP-b-CyD on taste properties of 1.50 mg
ml1 (4.275 mM) ranitidine hydrochloride generated using the sensors
SB2AC0, SB2ANO, SB2C00 and SB2AE1.Taste-masked formulations
PCA was employed to examine the taste masking capabilities of
HP-b-CyD on ranitidine hydrochloride by examining the
responses for mixes of the two substances. The Euclidean
distances between these formulations and ranitidine hydro-
chloride at each of the six concentration points were calculated
to better assess taste masking eﬃciencies. As presented in Table
1, the distance from ranitidine hydrochloride generally
increased from formulation with 1 : 1 molar ratio to formula-
tion with 1 : 5 molar ratio, indicating that as the molar ratio of
HP-b-CyD increased, the taste masking eﬃciency similarly
increased; this is of interest in that from this data the optimal
molar ratio is not simply 1 : 1.
The results for 1.50 mg ml1 (4.275 mM) ranitidine hydro-
chloride were chosen for illustration and presented on a PCA
map in Fig. 6. On the PCA map, data points for ranitidine
hydrochloride are located near the bottom right hand corner. It
is observed that with increasing molar ratio of HP-b-CyD to
ranitidine hydrochloride, the formulations were situated
further away from the pure drug substance. The 1 : 1molar ratio
formulation has a Euclidean distance of 1.29, 1 : 2 molar ratio
formulation has a value of 2.39, 1 : 3 molar ratio formulation
has a value of 2.54 while 1 : 4 and 1 : 5 molar ratio formulations
have values of 3.85 and 3.94 respectively. However, it is notable
(Table 1) that the Euclidean distance of taste-masked formula-
tions from 0.06mgml1 (0.171mM) of ranitidine hydrochloride
did not follow this trend, with inconsistent results with molar
ratio noted. These inconsistencies were anticipated as sensor
response anomalies were previously detected at 0.06 mg ml1
ranitidine hydrochloride and might have aﬀected the analysis
of sensor outputs.
In addition, it is observed that the Euclidean distance did
not show signicant increase in value at the formulations with
1 : 4 and 1 : 5 molar ratios; this may imply a maximum ratio forTable 1 Euclidean distances of the taste-masked formulations from ranit
refer to drug: HP-b-CyD
Concentration of
ranitidine hydrochloride (mg ml1)











This journal is © The Royal Society of Chemistry 2018taste masking eﬀectiveness, beyond which there is no advan-
tage in raising the HP-b-CyD concentration. This is potentially
highly useful in that the biosensor approach may give an indi-
cation to the formulator of maximum taste masking eﬃciency
when using a relatively expensive masking excipient.NMR studies
NMR studies produced more supporting evidence for the
inclusion of ranitidine hydrochloride into the central cavity of
HP-b-CyD. It should be noted that (2-hydroxypropyl)-b-cyclo-
dextrin used in this work is not structurally homogeneous, with
the average degree of substitution reported as 0.5–1.3 unit of 2-
hydroxypropyl (C3H7O) per glucose unit by the manufacturer.
From the integral intensities of the signals between 4.94–
5.50 ppm (H10) and 0.88–1.50 (H90) in the 1H NMR spectrum,
the degree of substitution is estimated as 0.71  0.02 for the
sample of (2-hydroxypropyl)-b-cyclodextrin used in this work.
Due to random substitution at diﬀerent glucose ring positions,
the 1H spectrum of HP-b-CyD is considerably more complex
than that of b-CyD. As can be seen from Fig. 7, in the high-
frequency region where proton H10 resonates at 5.09 ppm inidine hydrochloride at each individual concentration point. Molar ratios
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Fig. 7 The 1H NMR spectrum of the HP-b-CyD : ranitidine hydro-
chloride mixture at r ¼ 0.5. The chemical shifts of ranitidine hydro-
chloride are given in Table S5.†
Fig. 8 Selective TOCSY 1H NMR spectra of pure HP-b-CyD and HP-b-
CyD with increasing proportions of ranitidine hydrochloride, with the
selective pulse applied at the position of H10 at 5.11 ppm. A gradual
change in the position of the triplet H30 signal at 3.99 ppm in (a) is
observed on increasing proportions of ranitidine hydrochloride. The
spectrum of pure HP-b-CyD is shown in (a). Spectra of (b), (c) and (d)





















































































View Article Onlineb-CyD,30 we observe signals between 5.09–5.31 ppm appearing
as two sets of overlapping multiplets with centres of mass at
5.11 and 5.27 ppm due to protons H10 with (or without) 2-
hydroxypropyl substituents in diﬀerent positions. The signal at
5.11 ppm can be attributed to glucose rings with no HP
substituents or with HP substituents remote from the H10
proton, thus causing only very small changes of the chemical
shi (0–0.03 ppm) compared to that in b-CyD.30 Glucose rings
with HP substituents in the vicinity of proton H10 are likely to
cause larger shi of H10, and therefore the signal at 5.27 ppm is
attributed to H10 protons of glucose rings with HP substituents
in the vicinity of proton H10. For example, the HP substitution at
C2 of the glucose ring is estimated to lead to the increase of the
chemical shi of proton H10 by 0.23 ppm using ACD/I-Lab
database.
In order to simplify the spectrum selective TOCSY experi-
ments were employed. The selective pulse of the TOCSY pulse
sequence was applied at 5.11 ppm, which is narrower than that
at 5.37 ppm, hence providing better selectivity for the identi-
cation of other glucose protons from the rings in which the H10
proton resonates at 5.09–5.12 ppm. From the spectra shown in
Fig. 8, chemical shis of glucose ring protons were determined.
The chemical shis of HP-b-CyD protons in the presence of
increasing amounts of ranitidine hydrochloride is shown in
Table S4.† In order to assess the eﬀect of the inclusion of
ranitidine hydrochloride in HP-b-CyD, the change in chemical
shis (Dd) in the complex (dcomplex) relative to the chemical
shis of the same protons in the free components (dfree) was
followed, where Dd is dened as (dcomplex  dfree). The
complexation-induced chemical shis (Dd) were the most
signicant at H30 proton of HP-b-CyD (see numbering of HP-b-
CyD protons in Fig. 1). At r ¼ 0.7 (70% molar ratio of HP-b-CyD;
see Table S3†), the shi change was 30 ppb (Table S4†). At r ¼3570 | RSC Adv., 2018, 8, 3564–35730.5 (50% HP-b-CyD), the chemical shi change was 43.3 ppb,
while the value was 66.8 ppb at r ¼ 0.3 (30% HP-b-CyD). A
greater magnitude of change in the chemical shi for H30
protons of HP-b-CyD compared to other protons of HP-b-CyD
could be due to proximity of protons H30 to the aromatic furan
ring of ranitidine, which is likely to cause larger chemical shi
changes than other functionalities of ranitidine due to the
aromatic ring current eﬀects (i.e. shielding with the decrease of
1H chemical shis, if proton H30 is placed above the furan ring,
as observed experimentally). It is also interesting to note (see
Fig. 8 and Table S4†) that the level of H30 shi change was
greatest at the lowest ratio (r) of polymer to drug; this is
consistent with expectations that the higher drug loading would
result in a greater occupancy of the binding site on the HP-b-
CyD. In principle, an exchange model is also consistent with
this explanation: there are H30 sites with and without ranitidine
molecules nearby. The chemical shi we see for H30 of the host
is averaged between that of free H30 and bound H30 as a result of
fast diﬀusion of the guest molecules inside (or in and out of) the
host cavities. So, at higher loadings we will see larger chemical
shi change for H30 of the host molecules, simply because at
any instant we have more H30/guest pairs than H30/no guest.This journal is © The Royal Society of Chemistry 2018
Fig. 10 (A) Top view of the electrostatic surface of the donut shaped
HP-b-CyD. (B) Ranitidine (green) binds in the central cavity, making
hydrogen bonds with 60-OH and 80-OH groups of HP-b-CyD (yellow).
(C) Side and (D) end view of the positions of H30 protons (blue sphere)
in HP-b-CyD (E and F) top and side views of the spatial proximity





















































































View Article Online1H and 13C chemical shis of pure ranitidine hydrochloride
and in HP-b-CyD : ranitidine hydrochloride mixtures are
included in Table S5.† The largest chemical shi changes were
observed for protons H4 and H6, as well as for carbons C18,
C12, C2 and C10. Such changes could be attributed to proximity
of corresponding atoms to HP-b-CyD molecules or the changes
of the conformation of the ranitidine hydrochloride inside the
HP-b-CyD cavities compared to its preferred conformation in
D2O solution.
In addition to 1H and 13C chemical shi changes of host and
guest species, we have also sought direct evidence from NMR
experiments in order to conrm complexation of ranitidine and
HP-b-CyD molecules. Fig. 9 shows nuclear Overhauser eﬀects
(NOEs) of furan protons of ranitidine in the two-dimensional
(2D) NOESY spectrum of HP-b-CyD : ranitidine hydrochloride
mixture with r ¼ 0.7. Positive (shown in green) and negative
(shown in blue) NOEs are observed, which are usually charac-
teristic for small and high molecular weight species, respec-
tively. The observation of intermolecular negative NOEs
between ranitidine furan protons (at 6.41 and 6.68 ppm) and
HP-b-CyD cavity protons H30 and H50 (resonating at 3.96 and
3.88 ppm, respectively) conrms the inclusion of ranitidine
molecules inside the HP-b-CyD cavity.
A weaker intermolecular negative NOE is also observed
between the ranitidine furan proton H3 (at 6.42 ppm) and the
HP-b-CyD proton H80 (at 4.05 ppm). Similar intermolecular
NOEs were also observed for other complexes of HP-b-
CyD : ranitidine hydrochloride. Comparison of the volume
integral of the intermolecular NOE at 3.9–6.7 ppm relative to
that of the intramolecular NOE at 2.9–6.7 ppm, showed the
decrease of the intensity of the intermolecular NOE on
decreasing the ratio (r) of polymer to drug: 1.5 in r¼ 0.7, 1.1 in r
¼ 0.5 and 0.5 in r¼ 0.3. This, in principle, may suggest stronger
binding of the guest at the highest ratio of polymer to drug.Fig. 9 The 2D NOESY spectrum of the HP-b-CyD : ranitidine hydro-
chloride mixture with r ¼ 0.7, showing positive (in green) intra-
molecular and negative (in blue) intermolecular NOEs for ranitidine
furan protons.
This journal is © The Royal Society of Chemistry 2018Molecular modelling
In order to better understand the interactions between (2-
hydroxypropyl)-b-cyclodextrin and ranitidine, molecular dock-
ing studies were performed. The central cavity of the HP-b-CyD
has a diameter of 13.2 A, and is hence large enough to allow
ranitidine to penetrate into the interior (Fig. 10A). The dime-
thylamino group (N7) at one end of the drug molecule and the
nitrogen atom in the diamine group (N14) at the other form
direct hydrogen bonds with oxygen atoms at 60-OH and 80-0H of
the HP-b-CyD (Fig. 10B). The binding energy was calculated to
be 19.95 kcal mol1. Ranitidine docks with its furan ring in
close proximity to H30 (Fig. 10C–F). The molecular complex
between HP-b-CyD and ranitidine is therefore consistent with
results from NMR experiments, which indicated that the largest
chemical shis are for H30 proton and suggested that these are
associated with a close proximity of the furan ring of the drug to
this proton. Our modelling studies fully support this, suggest-
ing ring current eﬀects arising from the close proximity of the
furan ring of the ranitidine molecule.Conclusions
The present study demonstrates that taste masking eﬃciency
can be examined by sensor response measurements. Using the
TS-5000Z taste sensing system, sensor outputs were obtained
from various taste-masked formulations and further analysed





















































































View Article Onlinefrom the pure drug substance (ranitidine hydrochloride)
increased from the formulation with 1 : 1 molar ratio to
formulation with 1 : 5 molar ratio. This provided strong
evidence that with increasing molarity of HP-b-CyD in a formu-
lation, the bitter taste of the formulation decreased. These
results were further supported by the NMR studies. The 1H-
NMR spectra showed signicant complexation induced shis
when increasing proportions of ranitidine hydrochloride were
added to HP-b-CyD. The H30 protons of HP-b-CyD displayed the
greatest magnitude of change in terms of chemical shis as
compared to other protons of the glucose ring; this proton, as
well proton H50 are oriented inwards inside the b-CyD cavity (as
conrmed here using modelling studies). Further NMR
measurements revealed intermolecular NOEs between internal
protons H30 and H50 of the HP-b-CyD cavity and furan protons
of ranitidine hydrochloride, thus conrming their spatial
proximity. A plausible mode of structural interaction that is
consistent with the experimental data is also suggested using
molecular docking studies, predicting hydrogen bond interac-
tions between two nitrogen groups at either end of the molecule
with hydroxyl oxygen groups of HP-b-CyD, plus the docking
studies also indicated an interaction between the furan group of
the drug with the internal H30 proton of the HP-b-CyD, in
agreement with the NMR studies. The biosensor system used to
assess taste is primarily a potentiometric approach, hence it can
be seen that molecular interaction between the drug and HP-b-
CyD can be reasonably expected to reduce the electrode poten-
tial of the drug leading to a lower measurement for bitterness.
The study therefore indicates that the interaction between the
drug and complexing agent (conrmed using NMR and docking
studies) is reected by a change in taste, with an associated
decrease in bitterness predicted. This is signicant in that it
provides the rst stage for the development of a screening
approach for complexation that could allow identication of the
most promising formulations at an early stage, thus saving
considerable time and expense. The fact that the observed
biosensor responses may be supported by associated structural
studies provides a means of mechanistically supporting, and
potentially predicting, the taste assessment measurements.
The obvious question remains of how specically the
biosensor information translates to the biological environment,
but given the well-known physiological taste masking capability
of cyclodextrins it is entirely reasonable to suggest rstly a clear
causality between the complexation demonstrated here and the
reduction in taste suggested by the biosensor system and
secondly a putative causality between the complexation congu-
ration and the reduction in taste in vivo. This is signicant in that
it develops the discussion on how molecular conguration (and
shielding thereof) relates to human taste, a much larger issue
about which as yet little is known. Overall therefore the study has
provided a mechanistic link between complexation of an API
(ranitidine hydrochloride) with HP-b-CyD and the associated
taste as measured using a biosensor system.
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